When using the same questionnaire, we and others have shown the beneficial effects of glucagon-like peptide 1 receptor agonists (GLP-1 RAs), i.e., liraglutide and semaglutide, on body weight, as well as the multiple eating behaviors that were found in obese type 2 diabetic patients [10,14]. Here, GLP1R is linked to type 2 diabetes mellitus.